Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 2024 Apr 30.
Article in English | MEDLINE | ID: mdl-38687212

ABSTRACT

Proinflammatory cytokine levels and host genetic makeup are key determinants of Clostridioides difficile infection (CDI) outcomes. We previously reported that blocking the inflammatory cytokine macrophage migration inhibitory factor (MIF) ameliorates CDI. Here, we determined kinetics of MIF production and its association with a common genetic variant in leptin receptor (LEPR) using blood from patients with CDI. We found highest plasma MIF early after C difficile exposure and in individuals who express mutant/derived LEPR. Our data suggest that early-phase CDI provides a possible window of opportunity in which MIF targeting, potentially in combination with LEPR genotype, could have therapeutic utility.

2.
J Investig Med High Impact Case Rep ; 11: 23247096231156007, 2023.
Article in English | MEDLINE | ID: mdl-36799482

ABSTRACT

Histoplasma capsulatum is a geographically specific dimorphic fungus that can cause a spectrum of diseases. While most cases are asymptomatic pulmonary infections, in severe cases, particularly in immunocompromised patients, disseminated disease can occur. Histoplasmosis in California is limited to only a few case reports. In this article, we describe a rare case of disseminated histoplasmosis in a non-endemic region presenting with diagnostically challenging symptomatology, including altered mental status, status epilepticus, septic shock, and bilateral adrenal masses.


Subject(s)
Histoplasmosis , Lymphohistiocytosis, Hemophagocytic , Humans , Histoplasmosis/complications , Histoplasmosis/diagnosis , Histoplasmosis/microbiology , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/diagnosis , Histoplasma , California
3.
J Investig Med High Impact Case Rep ; 10: 23247096211051928, 2022.
Article in English | MEDLINE | ID: mdl-35225034

ABSTRACT

A 49-year-old man with no significant past medical history received dexamethasone as part of his treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Less than 3 weeks later, the patient developed acute respiratory distress syndrome. Radiological and serological testing led to a diagnosis of acute hypoxic miliary coccidioidomycosis. A 52-year-old man with a past medical history of chronic kidney disease (CKD) was treated with prednisone for focal segmental glomerulosclerosis (FSGS). Within 2 weeks, this patient developed bilateral lower extremity weakness. Radiology, serology, and lumbar puncture proved a diagnosis of reactivated coccidioidomycosis with miliary pattern and coccidioidomycosis meningoencephalitis with arachnoiditis. Whether treatment with glucocorticoids caused reactivation of coccidioidomycosis is discussed in this case series.


Subject(s)
COVID-19 Drug Treatment , Coccidioidomycosis , Respiratory Distress Syndrome , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Glucocorticoids/adverse effects , Humans , Male , Middle Aged , Respiratory Distress Syndrome/chemically induced , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL
...